Biotechnology Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus Research Biotechnology
Ionis Pharmaceuticals Inc (IONS) Q2 2024 Earnings: EPS of -$0.45 Beats Estimates, Revenue Surpasses Expectations at $225 Million
Ionis Pharmaceuticals Inc (IONS) released its 8-K filing on August 1, 2024, detailing its financial performance for the second quarter of 2024. Aug 01, 2024
GuruFocus Research Biotechnology
Sage Therapeutics Inc (SAGE) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth Amidst Strategic Challenges
Key insights from Sage Therapeutics Inc (SAGE) Q2 2024 earnings call reveal significant progress in prescription growth and strategic initiatives, despite ongoing financial and operational hurdles. Aug 01, 2024
GuruFocus Research Biotechnology
Vanda Pharmaceuticals Inc (VNDA) Q2 2024 Earnings Call Transcript Highlights: Revenue Growth Amidst Challenges
Despite a net loss and increased operating expenses, Vanda Pharmaceuticals Inc (VNDA) shows promising signs with new product launches and a strong cash position. Aug 01, 2024
GuruFocus Research Biotechnology
Jazz Pharmaceuticals PLC (JAZZ) Q2 2024 Earnings Call Transcript Highlights: Record Revenue and Strategic Insights
Jazz Pharmaceuticals PLC (JAZZ) reports its largest revenue quarter ever, driven by strong sales across key products and strategic investments. Aug 01, 2024